Cotransplantation of Cord Blood Hematopoietic Stem Cells and Culture-Expanded and GM-CSF-/SCF-Transfected Mesenchymal Stem Cells in SCID Mice by Han, Jin-Yeong et al.
INTRODUCTION
The bone marrow stroma contains primitive and potentially
self-renewing cells that can differentiate into various mesen-
chymal cells. These mesenchymal stem cells (MSC) are capa-
ble of supporting the expansion and differentiation of hema-
topoietic stem cells (HSC) in vitro and enhance hematopoi-
etic engraftment in vivo (1-5). Furthermore, MSC express
class I, but not class II, histocompatibility antigens, and they
are not immunogenic in in vitro assays and in preclinical or
clinical models.
Recently, it has been reported that there are mesenchymal
precursors in cord blood and peripheral blood of normal indi-
viduals. The results obtained demonstrate that after systemic
infusion of cord blood MSC into nude mice, human DNA
was found in the marrow and in ex vivo expanded stromal
cells grown from the marrow of transplanted animals. Several
groups also have reported bone and fat differentiation capac-
ity from cord blood-derived nonhematopoietic cells (6-10).
Despite the low initial frequency in cord blood, MSC have a
tremendous expansion potential in culture. Due to the lim-
ited number of HSC in a given cord blood unit, the outcome
of HSC transplantation (HSCT) could be improved by coen-
graftment of the MSC in addition to the hematopoietic pre-
cursors.
Several lines of evidence suggest that MSC produce some
essential hematopoietic growth factors (1-5). Based on these
reports, we hypothesized that exogenously administered MSC
with cytokine gene-transfected would show additive or aug-
mented effects on HSC expansion. In this study, mononuclear
cells (MNC) were harvested from cord blood and seeded in
long-term culture for ex vivo MSC expansion. We transfected
culture-expanded MSC with granulocyte macrophage-colony
stimulating factor (GM-CSF) and stem cell factor (SCF) cyto-
kine genes and then cotransplanted with cord blood MNC
in nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) mice to further promote HSC engraftment.
Although CD34+ cells can be selected for the preparation
of HSC, many cord blood HSCT practically use unselected
MNC. Therefore, we chose unselected MNC samples instead
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Mesenchymal stem cells (MSC) are multipotent in nature and believed to facilitate
the engraftment of hematopoietic stem cells (HSC) when transplanted simultane-
ously in animal studies and even in human trials. In this study, we transfected cul-
ture-expanded MSC with granulocyte macrophage-colony stimulating factor (GM-
CSF) and stem cell factor (SCF) cytokine genes and then cotransplanted with mono-
nuclear cells (MNC) to further promote HSC engraftment. MNC were harvested
from cord blood and seeded in long-term culture for ex vivo MSC expansion. A total
of 1× ×10
7 MNC plus MSC/ L were introduced to the tail vein of nonobese diabetic/
severe combined immunodeficiency mice. After 6-8 weeks later, homing and engraft-
ment of human cells were determined by flow cytometry and fluorescence in situ
hybridization studies. The total nucleated cell count and the engraftment of CD45+/
CD34+ cells and XX or XY positive human cells were significantly increased in cotrans-
planted mice and even higher with the cytokine gene-transfected MSC (GM-CSF>
SCF, p<0.05) than in transplantation of MNC alone. These results suggest that
MSC transfected with hematopoietic growth factor genes are capable of enhanc-
ing the hematopoietic engraftment. Delivering genes involved in homing and cell
adhesions, CXCR4 or VLA, would further increase the efficiency of stem cell trans-
plantation in the future.
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of selected samples as the source of stem cells for transplan-
tation. Our results show that human cells were significantly
increased in cotransplanted mice, and the number was even
higher with the cytokine gene-transfected MSC than with
transplantation of MNC alone. These data not only provide
direct evidence for the presence of MSC in cord blood, but
could also add to therapeutic profile of expanded MSC for
clinical use.
MATERIALS AND METHODS
Ex vivo MSC culture
Cord blood samples were collected from the umbilical vein
after full-term vaginal delivery. Informed consent was ob-
tained from all mothers. The mononuclear cell fractions from
cord blood were suspended at a concentration of 1×106 cells/
mL in MesenCult medium (StemCell Technologies, Inc.,
Vancouver, BC, Canada) and seeded in T-25 flasks. Cultures
were maintained at 37℃in humidified air and 5% CO2 with
a regular change of medium. After removal of non-adherent
cells, the adherent layer was further cultured until 80-90%
confluence. At this point, the cell population was expanded
by successive passage and resulting adherent cells were used
for experiments.
The adherent cells were detached with 0.05% trypsin-ethy-
lenediamine tetraacetic acid and washed with phosphate-
buffered saline (PBS). We observed morphology of detached
cells after Wright-Giemsa staining. The phenotype and puri-
ty of MSC were assessed by flow cytometry. The cells were
washed with PBS containing 2% bovine serum albumin, and
incubated with FITC-conjugated CD45 (BD Biosciences,
San Jose, CA, U.S.A.), PE-conjugated CD73 (BD Biosciences),
CD105 (DiNonA, Inc., Seoul, Korea), and CD166 (BD Bio-
sciences) on ice for 30 min in the dark. Those 3 monoclonal
antibodies were chosen because of the popularity and acces-
sibility. After fixation with 1% paraformaldehyde, flow cyto-
metry was performed on the FACSort instrument (Becton
Dickinson, San Jose, CA, U.S.A.).
GM-CSF/SCF gene transfection
For plasmid transfections, pEGFP-N1 DNA (Clontech,
Palo Alto, CA, U.S.A.) that encodes an enhanced green fluo-
rescent protein (EGFP) was used. Expanded MSC were trans-
fected with an EGFP-expressing vectors after cloning with
GM-CSF (pEGFP-N1/GM-CSF) or SCF (pEGFP-N1/SCF).
To create pEGFP-N1/GM-CSF or pEGFP-N1/SCF, human
peripheral blood monocytes were used for reverse transcrip-
tion-polymerase chain reaction. After sequencing of GM-
CSF and SCF genes, EcoRI was used for digestion to insert
cDNA3.1 and NotI was treated for SCF. Stable MSC trans-
fectants that expressed high levels of GFP were cloned by
limiting dilution and selected using 2 mg/mL neomycin
(Invitrogen Corp., Carlsbad, CA, U.S.A.). The GFP-express-
ing cells were screened by a microplate spectrofluorometer
(Shimadzu, Kyoto, Japan) and confirmed by an enzyme-linked
immunosorbent assay (ELISA) (R & D Systems, Minneapo-
lis, MN, U.S.A.). Stable clones of MSC with GFP and GM-
CSF or SCF were maintained in Dulbecco Modified Eagle
Medium (Gibco Laboratories, Grand Island, NY, U.S.A.) in
the presence of neomycin until transplantation. GFP-positive
MSC were visualized using a fluorescence microscope (Olym-
pus, Japan) and then used for transplantation to NOD/SCID
mice.
Transplantation and analysis of engraftment
NOD/SCID mice were purchased from Korea Research
Institute of Bioscience and Biotechnology (KRIBB, Daejeon,
Korea) and were maintained in sterile microisolator cages.
All mice received sublethal total body irradiation with a sin-
gle dose of 250 cGy. Twelve to 24 hr after irradiation, cells
in a final volume of 200  L were injected through the tail
vein. We designed 4 experimental groups, and each group
received 1×107 cells as a total: group 1 (n=5) received MNC
only, group 2 (n=7) received a mixture of MNC plus MSC,
0.5×107 respectively, group 3 (n=7) received a mixture of
MNC plus GM-CSF MSC, 0.5×107 respectively, and group
4 (n=6) received a mixture of MNC plus SCF MSC, 0.5×107
respectively, per mouse. MNC were isolated from cord blood
using a density gradient centrifugation. All cells were used
fresh without cryopreservation.
Six to 8 weeks later, blood samples were collected from the
retroorbital venous plexus of the NOD/SCID mice. An aliquot
of the blood was used for complete blood cell counts by Sys-
mex XE-2100 (Sysmex Corp., Kobe, Japan). Human cell
engraftment was detected by flow cytometry, using FITC-
conjugated CD45 (BD Biosciences) and PE-conjugated CD34
(BD Biosciences) antibodies. Positive cells were identified
by comparison with isotype controls. A part of venous blood
was also exposed to a hypotonic solution, and fixed in metha-
nol/acetic acid fixative. Nuclei were then stained with CEP
X (DXZ1) alpha satellite probe (Vysis, Inc., Downers Grove,
IL, U.S.A.) and CEP Y (DYZ1) satellite III probe (Vysis) for
fluorescence in situ hybridization (FISH) identification of
human cells. A total of at least 500-700 nuclei were exam-
ined in each case under a fluorescent microscope.
The results were expressed as mean±standard deviation.
Differences in engraftment percentages between experimen-
tal conditions were analyzed by Student-t test. A p value less
than 0.05 was considered statistically significant.
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blood analyzed. Primary cultures of MSC mainly consisted
of colonies of spindle-shaped fibroblastoid cells (Fig. 1A).
Confluence was usually reached after 2-3 weeks. Wright-Gie-
msa staining of detached MSC showed a large cell popula-
tion characterized by abundant cytoplasms with occasional
vacuoles and projections, fine nuclear chromatins, and one
or more nucleoli (Fig. 1B). Flow cytometry analyses demon-
strated that MSC expressed CD73, CD105, and CD166 in
all cases, but were negative for CD45 (Fig. 2). The purity of
expanded MSC was 85-97%.
At 24 hr after transfection, increased GFP expression was
identified both by spectrofluorometry and ELISA. The trans-
fected MSC showed visible GFP expression as early as 3 hr
after transfection. The highest efficiency of the transfection
was obtained after 5-7 days of culture both with pEGFP-N1/
GM-CSF and pEGFP-N1/SCF (Fig. 3, 4). On average 50-
70% of transfected MSC expressed GFP. Detached MSC were
then ready for transplantation. ELISA detected increased GM-
CSF levels from MSC cultures after transfection (273.78±
148.33 pg/mL) compared to those before transfection (34.35
±17.06 pg/mL) (p<0.05, n=4). SCF also increased from 1.30
±1.05 pg/mL to 24.10±20.21 pg/mL post transfection,
however, there were no statistical differences (p>0.05, n=4).
In MNC transplantation alone, the absolute numbers of
total nucleated cell (TNC) count was 0.08±0.04 (×103/L )
(n=5) comparable to 0.13±0.05 (×103/ L) (n=7) in mice
transplanted with MNC plus MSC (Table 1). However, higher
levels of human XX or XY cell by FISH (Fig. 5) were found
in transplantation of MNC plus MSC, 0.41±0.41 (×103/
L) vs. 1.52±0.81 (×103/ L) (p<0.05). Cotransplantation
of MNC and GM-CSF-transfected MSC most enhanced eng-
raftment. The TNC count, 4.63±0.96 (×103/ L) (n=7), and
the percentage of XX or XY cells, 5.68±0.58 (×103/ L),
were significantly higher (p<0.05) than those after transplan-
tation of MNC alone. Also, higher levels of TNC count, 2.93
±0.33 (×103/ L) (n=6), and XX or XY cells, 3.43±0.49
(×103/ L), were obtained following cotransplantation of
MNC plus SCF-transfected MSC (p<0.05). Engraftment study
with immunophenotypic analysis of CD45+/CD34+ cells
by flow cytometry showed similar results (Table 1, Fig. 6).
Fig. 1. Inverted phase contrast microscopic findings of cultured
cord blood MSC at passage 2, day 14 (A) (×150). Wright-Giem-
sa stained smear of the harvested MSC (B) (×1,000).
A B
Fig. 3. GM-CSF transfection studies. Microscopic images of phase
contrast (A) and fluorescence microscopes (B) before transfection.
Micrographs of phase contrast (C) and fluorescence microscopes
(D) post transfection day 5. The panel D shows GFP fluorescence,
indicating GFP-expressing MSC after transfection (×200).
A B
C D
Fig. 4. SCF transfection studies. Microscopic images of phase con-
trast (A) and fluorescence microscopes (B) before transfection.
Micrographs of phase contrast (C) and fluorescence microscopes
(D) post transfection day 7. The panel D shows GFP fluorescence,
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Fig. 2. Representative immunophenotypic analysis of MSC ex vivo
cultures from the cord blood. CD45-/CD73+ (95.7%), CD45-/CD
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DISCUSSION
Genetic modification of stem cells is an attractive target
for gene therapy because of their higher proliferative capaci-
ty and long-term survival compared with other somatic cells.
MSC have been demonstrated to be able to express exogenous
protein for an extended period of time and to maintain this
ability after transplantation in vitro (1, 11-14). Gene modi-
fied MSC are useful as therapeutic tools for various tumors.
MSC with forced expression of interferon beta were shown to
inhibit the growth of malignant cells in vivo (11, 12). Gene-
modification of MSC with therapeutic cytokines also clearly
augmented the antitumor effect and prolonged the survival
of tumor-bearing animals (13). Recently more efficient non-
viral DNA transfection methods have been introduced to ob-
tain stably transfected human cells (14, 15).
Ex vivo expanded MSC have been infused in several trans-
plantation studies. It is possible that a therapeutic benefit
from MSC could be obtained by local production of growth
factors and the provision of temporary immunosuppression.
Human MSC have a high expansion potential, genetic stabili-
ty, and reproducible characteristics proven in widely dis-
persed laboratories (1-3). No adverse events during or after
MSC infusion have been reported, and no ectopic tissue for-
mation has been observed.
Based on these results, we hypothesized that exogenously
administered MSC with cytokine gene-transfected would
show additive or augmented effects on HSC expansion. Among
the various cytokines, we have previously demonstrated that
the combination of SCF, thrombopoietin, and flt3 ligand is
sufficient for ex vivo expansion of cord blood (16). With the
addition of granulocyte (G)-CSF, the clonogenic and homing
potentials of cord blood were even higher, although statisti-
cally significant differences were not observed. Ramirez et
al. (17) also have shown that SCF, interleukin (IL)-3, IL-6,
and GM-CSF could induce the up-regulation of several adhe-
sion molecules involved in the mobilization and homing of
HSC. Currently GM-CSF is one of the most widely used
cytokines for the purpose of stem cell mobilization and for
the treatment of neutropenic patients. Therefore, we trans-
fected culture-expanded cord blood MSC with GM-CSF and
SCF cytokine genes, and then cotransplanted with cord blood
MNC in NOD/SCID mice to further promote HSC engraft-
ment. We demonstrated that human cells were significantly
increased in cotransplanted mice and even higher with the
cytokine gene-transfected MSC than in transplantation of
MNC alone. Cotransplantation of MNC and GM-CSF-trans-
fected MSC most enhanced engraftment.
Cotransplantation studies in animal models as well as in
humans showed that primary or culture-expanded MSC pro-
mote the engraftment of HSC (18-22). Cotransplantation of
MSC and cord blood (18, 19, 21) or mobilized peripheral









MNC alone 0.08±0.04 0.41±0.41 0.23±0.11
MNC plus MSC 0.13±0.05 >0.05 1.52±0.81 <0.05 0.83±0.65 >0.05
MNC plus GM-CSF MSC 4.63±0.96 <0.05 5.68±0.58 <0.05 5.92±1.95 <0.05
MNC plus SCF MSC 2.93±0.33 <0.05 3.43±0.49 <0.05 2.29±0.46 <0.05
Table 1. Comparison between HSC transplantation alone and cotransplantation of MNC plus MSC alone or MNC plus GM-CSF-/SCF-
transfected MSC
Fig. 5. XY human cells identified from the peripheral blood of NOD/
SCID mice 7 weeks after cotransplantation of GM-CSF-transfect-
ed cord blood MSC and MNC (×1,000). One orange signal indi-
cates one copy of the X chromosome, and one green signal indi-







Fig. 6. Representative CD34+/CD45+ cells (8.7%) detected from
venous blood of NOD/SCID mice 7 weeks after cotransplantation
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blood (20) CD34+ cells resulted in a significantly higher level
of engraftment than with transplantation of CD34+ cells
only. Cotransplantation of human leukocyte antigen (HLA)-
identical sibling culture-expanded MSC with an HLA-iden-
tical sibling HSC was also feasible and safe without imme-
diate infusional or late MSC-associated toxicities (22). The
mechanism of the enhancing effect is still unknown. Several
lines of evidence suggest that MSC produce several essential
hematopoietic growth factors including IL-6, IL-11, SCF,
leukemia inhibitory factor, and flt3 ligand and express adhe-
sion molecules and extracellular matrix proteins that are
known to play an important role in HSC homing such as
VCAM1, E-selectin, collagen I, and fibronectin (1-5, 20,
23). Different studies report that MSC have an immunomod-
ulatory effect and are able to suppress proliferation of T lym-
phocytes both by cell-cell interaction and via soluble factors
(22-25).
It has been claimed that there are mesenchymal precur-
sors in cord blood and peripheral blood of normal individu-
als (6-8, 26, 27). Despite the low initial frequency in cord
blood, MSC have a tremendous expansion potential in cul-
ture. Compared to bone marrow MSC, cord blood cultures
were slower to establish, but once established, the growth
was maintained over multiple passages. Using optimized iso-
lation and culture conditions, cells showing a characteristic
mesenchymal morphology and immune phenotype were iso-
lated. The frequency of MSC ranged from 0-2.3 clones per 1
×108 MNC. Due to the limited number of HSC in a given
cord blood unit, the outcome of HSC transplantation could
be improved by coengraftment of the MSC in addition to the
hematopoietic precursors.
Erices et al. (8) previously investigated the capability of
transplanted cord blood MSC to home and survive in the
marrow of nude mice. They have detected human DNA
after transplantation in the marrow of recipients as well as
in ex vivo-expanded stromal cells prepared from the marrow
of transplants. In this study we found that cord blood MSC
cotransplantation enhances human cell engraftment. This
enhancement was greater after cotransplantation of GM-CSF-
and SCF-transfected MSC. According to Wagner et al. (26)
several genes involved in mesodermal differentiation were
differently expressed on MSC from human bone marrow,
adipose tissue, or umbilical cord blood. These results implied
that potentials of mesodermal development might be differ-
ent depending on MSC preparations. By upregulating genes
involved in proliferation and homing of cord blood MSC,
this might contribute to establish a reliable genetic modifi-
cation system for clinical applications.
MSC are multipotent and believed to facilitate the engraft-
ment of HSC when transplanted simultaneously in animal
studies, and recently, even in human trials. In this study, we
transfected culture-expanded cord blood MSC with GM-CSF
and SCF cytokine genes and then cotransplanted with cord
blood HSC to further promote HSC engraftment. The TNC
count and the engraftment of CD45+/CD34+ cells and XX
or XY positive human cells were significantly increased in
cotransplanted mice and even higher with the cytokine gene-
transfected MSC (GM-CSF>SCF, p<0.05) than in transplan-
tation of HSC alone. Our results indicate that MSC may serve
as a platform to deliver hematopoietic growth factors in clin-
ical stem cell transplantation. Delivering genes involved in
homing and cell adhesions, CXCR4 or VLA, would further
increase the efficiency of stem cell transplantation in the future.
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